MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

Save

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when

Podcast of ACR17 - Day 4

Save

Care to learn what you missed at last weeks ACR 2017 meeting in San Diego?  Here are 4 one hour audio podcasts - each with a compliation of 2-4 minute reports from Drs. Cush, Kavanaugh, the RheumNow Faculty and other rheumatology thought leaders and researchers.  Another good way to learn from RheumNow.

The ACR17 RheumNow Week in Review - 10 November 2017

Save

This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr.

Podcast of ACR 17 - Day 3

Save

Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !

Practice Patterns of PJP Prophylaxis Among ID Physicians

Save

While the incidence of pneumocystis pneumonia (PJP) is low is patients with rheumatologic diseases the mortality is quite high compared to PJP in patients with HIV and infection can be prevented with appropriate prophylaxis.

Comparative Risk of Biologic Therapies in RA Patients Undergoing Elective Arthroplasty

Save

During today’s plenary session Micheal D. George, et al. presented results of a study that sought to compare risk of post-op infections in RA patients undergoing arthroplasty exposed to biologic DMARDs versus methotrexate.

2017 MIPs Reporting, What You Need to Know

Save

As a follow up to Dr. Will Harvey’s lecture at ACR 2017 (session title: Holy MACRA! How to Survive and Thrive in the New Era of MACRA, MIPS, and APMs), here are the keys for reporting your collections.

Who Are We Doing This For?

Save

We take many things for granted. I walked 11,151 steps today going from sessions to posters and exhibit halls to learn as much as I can to take back to my clinic so I can help my patients.  My feet were hurting, and my back bothered me as I tried to get comfortable for the next lecture; yet, these minor discomforts are nothing compared to what our patients experience on a daily basis.

Podcast of ACR17 Day 2

Save

Check out this compilation of our ACR17 Day 2 videocasts merged into a one hour podcast !

Tech Tools for Rheumatologists Version 3.0

Save

ACR 2017 - Day 1 Highlights

Save

Curtis and colleagues presented a plenary session that analyzed the duration of drug holidays and the risk of subsequent fractures (FX) in women starting bisphosphonates (BP).

RA and Cardiac Co-Morbidities

Save

We know that cardiovascular disease (CVD) is the leading cause of death in RA and that traditional risk factors do not fully account for increased risk.

Complementopathies: Redefining Old Diseases

Save

From Dr. Michelle Petri’s lecture on Antiphospholipid Syndrome Updates at ACR17 Review Course on Saturday, I learned that there is now a new class of diseases called the complementopathies.  This was the first time I heard of this term; how many patients did I misdiagnose who really had this and what are the ICD10 codes?!

The Red Eye in the Rheumatology Patient

Save

Professor Rosenbaum is well known for his expertise in rheumatic eye disease and he gave a great summary of how to approach your patient having a red eye.

Key Takeaways from ACR Review Course

Save

The ACR Review Course was superb once again from top to bottom, from Blue Fingers to Practical Treatment of RA. Every year I wonder if I should skip it, but each year I go. And I have never regretted it. Here are my take-home messages and “pearls” from the ACR Review Course.

2018 Changes for MOC: More Options, But Is It Better?

Save

Responding to criticisms that the 10 year maintenance of certification exam is expensive, time-consuming, and not reflective of clinical practice, the American Board of Internal Medicine recently issued changes to their requirements, allowing more options for physicians to recertify.

Lilly's New Data at ACR 2017

Save

Eli Lilly and Company (NYSE: LLY) announced that it will present new data for baricitinib and Taltz® (ixekizumab) at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting taking place Nov. 3-8, 2017, in San Diego, Calif.

Crescendo ACR Presentations

Save

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov.

ACR 2017 Playbook

Save

The annual ACR/ARHP meeting, which begins today, Sunday November 5th, is for many the premier meeting in rheumatology. The good news is that RheumNow and its expanded faculty will cover the meeting today and each day until Thursday. I haven’t missed an ACR meeting since 1984. In this span of 30 years I have acquired insights on how to navigate such a big meeting. When I say big, I mean over 15,000 attendees from over 100 countries swarming throughout a convention center that has the elements of the Texas state fair, Costco gone wild and a sold-out Margaritaville concert. Here's my ACR Playbook.

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Save

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein.